We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vascular endothelial growth factor antagonist peptides inhibit tumor growth and metastasis in breast cancer through repression of c-src and STAT3 genes.
- Authors
Bejari, Maedeh; Sasani, Soheila Talesh; Asghari, S. Mohsen; Kolshan, Mozhgan Nabatzade
- Abstract
Background: Breast cancer is one of the most decisive causes of cancer death in women worldwide. Cancer progression and tumor metastasis depend on angiogenesis. Vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) are critically required for tumor angiogenesis. Src is involved in many of the VEGF-mediated pathways. The VEGFRs activate Src via different mechanisms. Given that Src activates STAT3 (signal transducers and activators of transcription) repressing apoptosis and promoting the cell cycle, it may be an important object for cancer treatment. Methods and results: A series of VEGF antagonistic peptides, referred to as VGB 1,3 and 4, were designed to bind and block both VEGFR1 and VEGFR2 inhibiting the proliferation of different tumoral cells. We investigated c-Src and STAT3 gene expression changes in murine 4T1 tumors treated by the VGBs. The treated group received 1 and 10 mg kg−1 of the peptides, while the control mice received PBS, intraperitoneally for two weeks. Both of the groups underwent a resection of breast tissue 14 days after treatment. The results of qRT-PCR showed that the expression levels of c-Src and STAT3 genes were significantly decreased, in a dose-dependent manner, after treatment with the different types of VEGF antagonist peptides, compared to the control groups (P < 0.05). The groups treated with 1 mg kg−1 of all three types of VGB showed decreased expression of c-Src and STAT3 less than the groups receiving 10 mg kg−1 of the anti-angiogenic peptides. Conclusions: In conclusion, peptides VGB1, 3, and 4, could be effective therapeutic molecules in breast cancer by inhibiting angiogenesis and progression of the disease.
- Subjects
BREAST; VASCULAR endothelial growth factor antagonists; METASTATIC breast cancer; METASTASIS; TUMOR growth; STAT proteins; VASCULAR endothelial growth factors
- Publication
Molecular Biology Reports, 2023, Vol 50, Issue 11, p9213
- ISSN
0301-4851
- Publication type
Article
- DOI
10.1007/s11033-023-08822-6